Patents by Inventor Alberto Martini

Alberto Martini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11903650
    Abstract: A method for providing clinical support for surgical guidance during robotic surgery.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: February 20, 2024
    Inventors: Ardeshir Rastinehad, Alberto Martini
  • Publication number: 20210068900
    Abstract: A method for providing clinical support for surgical guidance during robotic surgery.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 11, 2021
    Inventors: Ardeshir Rastinehad, Alberto Martini
  • Publication number: 20160280776
    Abstract: The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of JRA in a subject.
    Type: Application
    Filed: November 9, 2015
    Publication date: September 29, 2016
    Inventors: John R. Medich, Nicolino Ruperto, Alberto Martini, Daniel J. Lovell, Edward H. Giannini
  • Patent number: 7790158
    Abstract: The current invention provides for methods of immunotherapy using a combination of epitope-specific and cytokine or anticytokine immunotherapy. The method provides for modulation of pathogenic immune responses and includes the identification of molecules comprising specific epitopes involved in a particular disease state of interest, administration of the epitope-specific molecule in conjunction with the cytokine or anticytokine, and downstream modification of the administration of the cytokine/anticytokine relative to the administration of the epitope-specific molecule.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: September 7, 2010
    Assignee: The Regents of the University of California
    Inventors: Salvatore Albani, Alberto Martini
  • Publication number: 20080187550
    Abstract: A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.
    Type: Application
    Filed: November 12, 2007
    Publication date: August 7, 2008
    Inventors: Salvatore Albani, Dennis A. Carson, Berent J. Prakken, Alberto Martini
  • Publication number: 20080118496
    Abstract: The invention provides methods, uses and compositions for the treatment of juvenile rheumatoid arthritis (JRA). The invention describes methods and uses for treating JRA, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to prevent flare-ups associated with JRA. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of JRA in a subject.
    Type: Application
    Filed: June 11, 2007
    Publication date: May 22, 2008
    Inventors: John R. Medich, Nicolino Ruperto, Alberto Martini, Daniel J. Lovell, Edward Giannini
  • Patent number: 7301005
    Abstract: A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: November 27, 2007
    Inventors: Salvatore Albani, Dennis A. Carson, Berent J Prakken, Alberto Martini
  • Publication number: 20060093574
    Abstract: The current invention provides for methods of immunotherapy using a combination of epitope-specific and cytokine or anticytokine immunotherapy. The method provides for modulation of pathogenic immune responses and includes the identification of molecules comprising specific epitopes involved in a particular disease state of interest, administration of the epitope-specific molecule in conjunction with the cytokine or anticytokine, and downstream modification of the administration of the cytokine/anticytokine relative to the administration of the epitope-specific molecule.
    Type: Application
    Filed: September 25, 2002
    Publication date: May 4, 2006
    Inventors: Salvatore Albani, Alberto Martini
  • Publication number: 20030031679
    Abstract: A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.
    Type: Application
    Filed: October 31, 2001
    Publication date: February 13, 2003
    Inventors: Salvatore Albani, Dennis A. Carson, Berent J. Prakken, Alberto Martini